ClinConnect ClinConnect Logo
Search / Trial NCT00000613

CVD Risk and Health in Postmenopausal Phytoestrogen Users

Launched by NATIONAL HEART, LUNG, AND BLOOD INSTITUTE (NHLBI) · Oct 27, 1999

Trial Information

Current as of May 09, 2025

Completed

Keywords

ClinConnect Summary

BACKGROUND:

Estrogen replacement therapy is beneficial for heart disease risk factors as well as for bone density. However, a large proportion of postmenopausal women are not compliant with therapeutic regimens. Phytoestrogens are naturally occurring compounds found in plants and soy products that have estrogenic effects, and may represent an alternative treatment for the prevention of heart disease and osteoporosis in postmenopausal women. However, few intervention trials have examined the extent to which it is possible to improve heart disease risk factors, bone density, and quality of l...

Gender

FEMALE

Eligibility criteria

  • Postmenopausal women, ages 45 to 74.

About National Heart, Lung, And Blood Institute (Nhlbi)

The National Heart, Lung, and Blood Institute (NHLBI) is a leading component of the National Institutes of Health (NIH), dedicated to advancing research and clinical trials focused on cardiovascular, pulmonary, and hematologic diseases. With a mission to improve public health through innovative research, the NHLBI supports a wide range of studies aimed at understanding, preventing, and treating heart and lung conditions. By collaborating with academic institutions, healthcare providers, and patient communities, the NHLBI strives to translate scientific discoveries into effective clinical practices, ultimately enhancing the quality of life for individuals affected by these critical health issues.

Locations

Patients applied

0 patients applied

Trial Officials

Donna Kritz-Silverstein

University of California, San Diego

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials